Ensign Peak Advisors’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Ensign Peak Advisors’s Portfolio CMPI Stock Details CMPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-93,334	Closed	-$268K	–	2279
2021 Q4	$268K	Sell	93,334 -26,581	-22%	-$99K	﹤0.01%	1851
2021 Q3	$476K	Hold	119,915	–	–	﹤0.01%	1632
2021 Q2	$714K	Hold	119,915	–	–	﹤0.01%	1527
2021 Q1	$1.46M	Hold	119,915	–	–	﹤0.01%	1264
2020 Q4	$1.75M	Hold	119,915	–	–	﹤0.01%	1141
2020 Q3	$1.38M	Buy	+119,915	New	+$1.54M	﹤0.01%	1167

Other funds holding CMPI

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

CCP

Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Ensign Peak Advisors's CMPI Position: Q1 2022 in Review

Ensign Peak Advisors sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q1 2022, closing a stake of 93,334 shares — an estimated $268K sold.

Ensign Peak Advisors first reported a position in CMPI in Q3 2020 and held it in 6 quarters. The position peaked at $1.75M in Q4 2020. 26 funds tracked by Wall St. Rank hold CMPI as of Q1 2022.

Ensign Peak Advisors reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Ensign Peak Advisors sold 93,334 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $268K.
Ensign Peak Advisors first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 6 quarters.
Ensign Peak Advisors's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $1.75M in Q4 2020.
26 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on Ensign Peak Advisors's 13F filing for Q1 2022, filed 16 May 2022.